Global Sensorimotor Neuropathy Market By Type (Diabetic Neuropathy, Hereditary Neuropathy, Charcot-Marie-Tooth Disease, and Other Types), By Diagnosis (EMGs and Motor Nerve Conduction Test, Specialized DNA Blood Tests, Molecular Genetic Testing, and Others), By Treatment (Medications, Physical therapy, Surgery, and Other Treatment Types), By Distribution Channel (Hospital Pharmacies and Retail & Online Pharmacies), End-User (Hospitals, Homecare, Specialty Clinics, and Other End-Users), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032
- Published date: Oct 2023
- Report ID: 101979
- Number of Pages: 389
- Report Overview
- Key Takeaways
- By Type Analysis
- By Diagnosis Analysis
- By Treatment Analysis
- By Distribution Channel Analysis
- Key Market Segments
- Impact of Macroeconomic Factors
- Latest Trends
- Regional Analysis
- Key Regions
- Key Players Analysis
- Market Key Players
- Recent Development
- Report Scope
Global Sensorimotor Neuropathy Market size is expected to be worth around USD 12.2 Billion by 2032 from USD 7.0 Billion in 2022, growing at a CAGR of 5.9 % during the forecast period from 2023 to 2032.
Sensorimotor neuropathy is a disorder of the peripheral nerves responsible for transmitting information between the brain and spinal cord to other parts of the body. It may present as muscle weakness, numbness, tingling, or pain in various locations on the body. Various medical conditions, such as diabetes, autoimmune disorders, infections, alcoholism, and hereditary factors, can cause sensorimotor neuropathy. Segmenting patients based on their underlying cause helps identify those most likely to benefit from specific treatment approaches.
Sensorimotor neuropathy occurs when nerve damage affects sensory nerves, which transmit sensation (such as touch, pain, and temperature) from the body to the brain, and motor nerves, which control muscle movement. This may result in symptoms such as muscle weakness, loss of coordination, numbness or tingling in affected areas, and difficulty with balance or walking. Treatment may involve addressing the underlying cause and administering medications for pain management and muscle weakness. Physical and occupational therapy may also be recommended to increase strength and mobility.
*Actual Numbers Might Vary In The Final Report
- Sensorimotor neuropathy is a disease of the nervous system, that results in reduced mobility and sensation.
- When segmented based on type, Diabetic Neuropathy contributes the most to the market.
- By diagnosis, the Electromyography (EMG) segment remains the most dominant segment in the Sensorimotor Neuropathy Market in 2022.
- As far as treatment is considered, medications segment generates the most revenue, with a market share of over 33%.
- Hospital Pharmacies are the most contributing end users.
- Regionally, North America is the region with the highest revenue generation, with an estimates 38.5% market share in 2022.
- Asia Pacific is expected to undergo exponential growth in the forecast period.
By Type Analysis
Based on type, the global sensorimotor neuropathy market is segmented into Diabetic Neuropathy, Hereditary Neuropathy, Charcot-Marie-Tooth Disease, Guillain-Barre Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), sensorimotor polyneuropathy, Toxic Neuropathy and Infectious Neuropathy.
Diabetic Neuropathy is the most prevalent type, and it’s linked with diabetes mellitus; it affects nerves in the legs and feet, causing pain, tingling sensation, and weakness, and chemotherapy drugs damage nerves responsible for sensation and movement, causing symptoms such as numbness/tingling sensation or movement.
By Diagnosis Analysis
Based on the diagnosis, the global sensorimotor neuropathy market is segmented into EMGs and Motor Nerve Conduction Tests, Specialized DNA Blood Tests, Molecular Genetic Testing, and Others. Electromyography (EMG) measures electrical activity in muscles; it can help identify muscle damage or weakness caused by nerve dysfunction. Blood tests may identify underlying medical conditions causing sensorimotor neuropathy, such as diabetes, autoimmune disorders, or vitamin deficiencies.
By Treatment Analysis
Based on disease treatment, the global sensorimotor neuropathy market is divided into medications, physical therapy, occupational therapy, transcutaneous electrical nerve stimulation (TENs), and surgery. Certain medications may help relieve pain, reduce inflammation, and manage other symptoms associated with sensorimotor neuropathy. These may include painkillers, anti-inflammatory drugs, and antidepressants. Physical therapy is another option to improve muscle strength, flexibility, and coordination.
In addition, exercises, stretching, and other techniques may be employed to strengthen muscles and nerves affected by an injury. Finally, occupational therapy also has the potential to enhance daily activities such as dressing, eating, and bathing by using adaptive devices or other tools that make these tasks simpler.
By Distribution Channel Analysis
Products such as over-the-counter pain relievers, topical creams, and supplements may be distributed through pharmacy and drugstore chains. In addition, medical equipment such as braces, splints, and orthotics for individuals with neurological conditions can be obtained from medical supply companies specializing in this therapy area. Prescription medications and devices may also be distributed through hospitals and clinics specializing in treating neurological conditions.
Key Market Segments
- Diabetic Neuropathy
- Hereditary Neuropathy
- Charcot-Marie-Tooth Disease
- Guillain-Barre Syndrome
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Toxic Neuropathy
- Infectious Neuropathy
- EMGs and Motor Nerve Conduction Test
- Specialized DNA Blood Tests
- Molecular Genetic Testing
- Physical therapy
- Occupational therapy
- Transcutaneous electrical nerve stimulation (TENS)
By Distribution Channel
- Hospital Pharmacies
- Retail & Online Pharmacies
The rising prevalence of diabetes and other chronic illnesses such as HIV, cancer, and autoimmune diseases contribute to an uptick in sensorimotor neuropathy cases; thus, increasing demand for effective treatments will increase. In addition, advances in medical technology, such as advanced imaging techniques, biomarkers, and gene therapies, are expected to fuel growth in the sensorimotor neuropathy market by providing more precise diagnoses and tailored treatments.
Furthermore, the growing healthcare infrastructure in developing economies such as India and China is projected to fuel growth in the sensorimotor neuropathy market by providing patients with more access to diagnosis and treatment options. In addition, the market for sensorimotor neuropathy is expected to experience growth due to increased investment in research and development by pharmaceutical and biotechnology companies to develop new treatments.
Furthermore, increasing patient awareness regarding the potential complications associated with sensorimotor neuropathy as well as the need for early diagnosis and treatment, are expected to fuel demand within this space.
Sensorimotor neuropathy can be expensive to treat, particularly for patients in developing countries. This will likely limit access to treatments and hamper market growth. In addition, due to a lack of awareness and access to diagnostic facilities in certain regions, early diagnosis and treatment for sensorimotor neuropathy can be delayed, leading to further progression and worsening symptoms. Unfortunately, there are limited treatment options available for this disorder.
This could exacerbate competition among existing treatments, restricting market expansion and limiting innovation. In addition, some treatments for sensorimotor neuropathy can have significant side effects, which could limit their use among those with other medical issues. Finally, strict regulatory policies and the high cost and time involved in obtaining regulatory approvals could obstruct new players from entering the market or delay the introduction of novel therapies.
Technology advances such as gene therapy, cell therapy, and biomarker identification are creating new possibilities for developing treatments for sensorimotor neuropathy. These therapies may offer improved effectiveness and safety profiles, potentially fueling the market’s growth. Investment in research and development is anticipated to fuel innovation in the sensorimotor neuropathy market, creating new treatments and diagnostic tools that could enhance patient outcomes and expand market share.
Patients and healthcare providers are increasingly searching for non-invasive treatments for sensorimotor neuropathy, such as electrotherapy, magnetic therapy, and other forms of physical therapy. This trend is expected to fuel the growth in demand for these treatments.
In addition, increased awareness among healthcare providers regarding the significance of early diagnosis and intervention for sensorimotor neuropathy is expected to fuel growth in this market by increasing demand for diagnostic tests and treatments. Furthermore, as populations age, the incidence of the disorder increases, creating an even greater need for diagnosis and treatment services.
Impact of Macroeconomic Factors
As far as macroeconomic factors are considered, inflation exercises the most influence on the market. Inflation has been rising over the last few years and has done considerable damage to economies worldwide. The sensorimotor neuropathy market is no exception. The cost of living has been affected across the globe, which has resulted in change in customer behavior patterns. During the times of economic distress, customers tend to spend on the necessities while other expenses are put off.
Medical expenses are also often ignored. This has major consequences for the sensorimotor neuropathy market, seeing that patients might postpone seeking medical attention due to soaring healthcare costs.
There is increasing awareness of the significance of early diagnosis and intervention for sensorimotor neuropathy, particularly among individuals with diabetes or other chronic illnesses. This trend is expected to drive demand for diagnostic tests and treatments. In addition, there is an increasing trend toward non-invasive treatments for sensorimotor neuropathy, such as electrotherapy, magnetic therapy, and other forms of physical therapy.
This trend is expected to persist as patients and healthcare providers look for less invasive treatments with fewer side effects. Modern imaging technologies, such as magnetic resonance imaging (MRI), computed tomography (CT), and ultrasound, give healthcare providers more tools for diagnosing and monitoring sensorimotor neuropathy.
This trend is expected to persist as more technologies become accessible. With the rising prevalence of chronic diseases like diabetes and autoimmune disorders, sensorimotor neuropathy could see an uptick in incidence, thus necessitating demand for diagnostic tests and treatments.
Pharmaceutical and biotechnology companies are investing increasingly in research and development to discover new therapies for sensorimotor neuropathy. This trend is expected to continue as advances such as gene therapy, cell therapy, and biomarker identification open new avenues for developing effective treatments.
North America is the leading market for sensorimotor neuropathy due to the high prevalence of diabetes and other chronic diseases in this region. Major pharmaceutical and biotechnology companies and established healthcare infrastructure are expected to fuel growth in this market.
Europe also presents a significant opportunity due to high diabetes prevalence, which drives demand for diagnostic tests and treatments. Furthermore, Europe boasts an established healthcare infrastructure as well as a strong focus on research and development which should encourage innovation within this space.
Asia Pacific is the fastest-growing market for sensorimotor neuropathy, driven by an increase in diabetes and other chronic diseases in the region. With a large population base and improving healthcare infrastructure, this region is expected to experience rapid growth within this market.
- The UK
- Rest of Europe
- South Korea
- New Zealand
- Rest of APAC
- Rest of Latin America
Middle East & Africa
- South Africa
- Saudi Arabia
- Rest of MEA
Key Players Analysis
The market is highly competitive and features several established players. As a result, companies are investing in research and development to create new treatments for sensorimotor neuropathy to gain an edge in the marketplace. Eli Lilly & Company, Pfizer Inc., and GlaxoSmithKline plc are the leading players by market share; these firms are focused on creating treatments by using their research & development capabilities to drive innovation within this space.
Market Key Players
With many local and regional players’ presence, the sensorimotor neuropathy market is fragmented. As a result, market players are subject to intense competition from top players, particularly those with strong brand recognition and high distribution networks. As a result, companies have gained various expansion strategies, such as partnerships and product launches, to stay on top of the market.
The following are some of the major players in the global sensorimotor neuropathy industry
- Pfizer Inc.
- Eli Lilly and Company
- Novartis AG
- Abbott Laboratories
- GlaxoSmithKline plc
- Johnson & Johnson
- Merck & Co., Inc.
- Sanofi S.A.
- Biogen Inc.
- Teva Pharmaceutical Industries Ltd.
- Other Key Players
- October 2023: Eli Lilly and Co. purchased POINT Biopharma, a business specialising in innovative therapeutics. Over US$ 1.2 billion were paid for the deal, with per share price being US$ 12.50.
- October 2023: Sanofi SA establsihed a research site at Griffith University. The partnership under which this center was opened is part of the TSH, a US$ 280 million collaboration between Queensland and Sanofi.
Report Features Description Market Value (2022) USD 7.0 Billion Forecast Revenue (2032) USD 12.2 Billion CAGR (2023-2032) 5.9% Base Year for Estimation 2022 Historic Period 2016-2021 Forecast Period 2023-2032 Report Coverage Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive Landscape, Recent Developments Segments Covered By Type – Diabetic Neuropathy, Hereditary Neuropathy, Charcot-Marie-Tooth Disease, Guillain-Barre Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Toxic Neuropathy, Infectious Neuropathy, By Diagnosis – EMGs and Motor Nerve Conduction Tests, Specialized DNA Blood Tests, Molecular Genetic Testing, and Others, By Treatment – Medications, Physical therapy, Occupational therapy,
Transcutaneous electrical nerve stimulation (TENS), and Surgery, By Distribution Channel – Hospital Pharmacies, Retail & Online Pharmacies
Regional Analysis North America – US, Canada; Europe – Germany, France, The UK, Spain, Italy, Russia, Netherlands, Rest of Europe; Asia Pacific – China, Japan, South Korea, India, New Zealand, Singapore, Thailand, Vietnam, Rest of APAC; Latin America – Brazil, Mexico, Rest of Latin America; Middle East & Africa – South Africa, Saudi Arabia, UAE, Rest of MEA. Competitive Landscape Pfizer Inc., Eli Lilly, and Company, Novartis AG, Abbott Laboratories, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Sanofi S.A., Biogen Inc., Teva Pharmaceutical Industries Ltd., Other Key Players Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. Purchase Options We have three licenses to opt for Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF)
Frequently Asked Questions (FAQ)What is sensorimotor neuropathy?
Sensorimotor neuropathy is a condition that affects the nerves responsible for both sensation (feeling) and motor function (muscle movement).How big is the sensorimotor neuropathy Market?
The global sensorimotor neuropathy Market size was estimated at USD 7.2 billion in 2022 and is expected to reach USD 12.2 billion in 2032.What is the sensorimotor neuropathy Market growth?
The global sensorimotor neuropathy Market is expected to grow at a compound annual growth rate of 5.9 %. From 2023 To 2032Who are the key companies/players in the sensorimotor neuropathy Market?
Some of the key players in the sensorimotor neuropathy Markets are Pfizer Inc., Eli Lilly and Company, Novartis AG, Abbott Laboratories, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Sanofi S.A., Biogen Inc., Teva Pharmaceutical Industries Ltd., Other Key PlayersWhat causes sensorimotor neuropathy?
Sensorimotor neuropathy can be caused by various factors, including diabetes, autoimmune diseases, infections, and exposure to toxins.How is sensorimotor neuropathy diagnosed?
Diagnosis typically involves a physical examination, nerve conduction studies, electromyography, and blood tests to identify the underlying cause.What are the common symptoms of sensorimotor neuropathy?
Common symptoms include numbness, tingling, weakness, and pain in the affected areas, often starting in the hands and feet.Is sensorimotor neuropathy treatable?
Treatment options aim to manage symptoms and address the underlying cause. They may include medications, physical therapy, and lifestyle changes.
- Pfizer Inc Company Profile
- Eli Lilly and Company
- Novartis AG Company Profile
- Abbott Laboratories
- GlaxoSmithKline plc
- Johnson & Johnson
- Merck & Co., Inc.
- Sanofi S.A.
- Biogen Inc.
- Teva Pharmaceutical Industries Ltd. Company Profile
- Other Key Players
| Single User
USD / per unit
| Multi User
USD / per unit
| Corporate User
USD / per unit
|Report Library Access
|Data Set (Excel)
|Company Profile Library Access
|up to 10 hrs work
|up to 30 hrs work
|up to 20 hrs
|up to 40 hrs
|up to 50 hrs
|Up to 20% off on next purchase
|Up to 25% off on next purchase
|Up to 30% off on next purchase
|Buy Now ($ 3,499)
|Buy Now ($ 4,299)
|Buy Now ($ 4,999)